Cellectis Reports $211M Cash Runway Into H2 2027 and 100% ORR in Phase 2 Trial
Cellectis ended 2025 with $211 million in cash, equivalents and fixed-term deposits, securing financing into H2 2027 for its CAR-T pipeline. Its pivotal Phase 2 BALLI-01 trial for lasme-cel achieved 100% ORR in the target population with all patients becoming transplant-eligible and an interim analysis due in Q4 2026.
1. Full Year 2025 Financial Results
Cellectis closed 2025 with $211 million in cash, cash equivalents and fixed-term deposits, including $144.8 million in fixed-term deposits and $4.4 million in restricted cash, providing funding into the second half of 2027 and underpinning its ongoing clinical development.
2. Lasme-cel Phase 2 Interim Analysis and BLA Timeline
The pivotal Phase 2 BALLI-01 trial in relapsed or refractory B-ALL follows Phase 1 data showing 83% ORR at the RP2D and 100% ORR with universal transplant eligibility in the target cohort; the first interim analysis is expected in Q4 2026, with a Biologics License Application planned for 2028.
3. Eti-cel Phase 1 Trial in r/r NHL
In the NATHALI-01 Phase 1 study for relapsed or refractory NHL, eti-cel achieved an 88% overall response rate and 63% complete response rate at the current dose level among patients with prior CD19 CAR-T exposure; an IL-2 combination cohort is now enrolling and full data are anticipated in Q4 2026.
4. Collaborations and Preclinical Advances
Cellectis is collaborating with Servier through Allogene on the ALPHA3 randomized Phase 2 consolidation trial in LBCL, with an interim futility analysis on MRD clearance planned for April 2026, and advancing joint research with AstraZeneca; preclinical work on cssDNA templates and TALE base editors has demonstrated over 40% knock-in efficiency and precise C-to-T editing without off-target effects.